Improving mRNA vaccines with extracellular vesicle-associated immunogens
使用细胞外囊泡相关免疫原改进 mRNA 疫苗
基本信息
- 批准号:10850617
- 负责人:
- 金额:$ 18.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-11-09 至 2024-10-31
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVActing OutAdenovirus VectorAnimalsAntibody FormationAntibody ResponseAntibody titer measurementAntigen-Presenting CellsAntigensBehaviorCOVID-19COVID-19 vaccineCapsid ProteinsCarrier ProteinsCell FractionCell LineCell membraneCellsCharacteristicsCommunicable DiseasesDNADataDevelopmentDoseEffectivenessEukaryotic CellFeline Immunodeficiency VirusFluzoneFormulationGlycoproteinsHIVHIV-1HemagglutininHumanImmuneImprove AccessInfluenza A virusInjectionsInterferonsMembraneMessenger RNAModificationMolecular ConformationMusNonstructural ProteinPatientsPerformancePreparationProductionProteinsRNA vaccineRecombinantsReportingResistanceRouteSARS-CoV-2 spike proteinSamplingSerumSiteStructureSubunit VaccinesTailTertiary Protein StructureTestingTransfectionTranslatingVaccinatedVaccinesViralViral AntigensViral Envelope ProteinsViral Matrix ProteinsViral ProteinsViral VaccinesVirusVirus DiseasesWorkadaptive immunityantagonistantigen bindingantigen testcellular transductionchicken eggdesigndraining lymph nodeefficacy testingempowermentenv Gene Productsexosomeexperimental studyextracellular vesiclesimmunogenicimmunogenicityimprovedin vivoinfluenza virus vaccineinterestiterative designlipid nanoparticlemanufacturing processmicrovesiclespanaceapathogenpreventprocess optimizationresistance mechanismresponsescaffoldsuccesstissue culturevaccine deliveryvaccine efficacyvaccine immunogenicityvaccine platformvector vaccine
项目摘要
Abstract
The central hypothesis of this proposal is that the efficacy of mRNA vaccines that deliver membrane-anchored
immunogens can be improved by localizing the immunogen to extracellular vesicles (EVs, small membrane-
limited structures shed by eukaryotic cells). Our rationale is that EVs provide a natural scaffold for immunogen
multimerization while also enabling membrane-bound antigens to access antigen presenting cells, both local to
the site of injection, and in the draining lymph node.
To localize immunogens to EVs and promote EV shedding we propose two complimentary approaches. In Aim
1, we will append a viral “late domain” to the carboxy terminus of our immunogen. Viral late domains are small
protein domains, usually associated with a matrix or capsid protein, used by enveloped viruses to facilitate
budding and egress. We have found that these domains can act out of context; fusing a late domain from
feline immunodeficiency virus Gag to a SARS-CoV-2 spike protein immunogen caused the immunogen to re-
localize to EVs and improved its immunogenicity nearly two-fold. We will expand this work by testing late
domains from other viruses for their ability to promote EV localization and/or production. We will thoroughly
characterize these EVs to determine correlates of vaccine immunogenicity.
In Aim 2, we will modify our immunogens to overcome the activity of the host anti-viral restriction factor BST-2
(a.k.a. tetherin). Tetherin inhibits viral egress by “tethering” budding enveloped viruses to the host cell
membranes and also inhibits the release of EVs by the same mechanism. Therefore, we will explore
strategies for antagonizing tetherin in order to promote release of our immunogen-laden EVs. Enveloped
viruses have evolved different strategies for tetherin evasion that we will attempt to incorporate into our
immunogen designs. Indeed, we have identified a portion of the SARS-CoV-2 spike protein that we suspect is
responsible for tetherin antagonism. Incorporating this S protein domain into our immunogen dramatically
increases the amount of immunogen recovered from EV fractions of tissue culture supernatants. We will also
explore similar strategies based on tetherin resistance mechanisms from other viruses.
Finally, in Aim 3, promising immunogen design strategies in the context of different viral envelope protein
immunogens (SARS-CoV-2, influenza A virus, HIV) will be compared in mice. These tests will allow us to
establish correlations between the behavior of our vaccine immunogens in tissue culture (quantity and
characteristics of the EVs, cytoxicity, etc.) and performance of the vaccine in vivo and determine if our
modifications universally improve vaccine efficacy, or if particular immunogen designs are better suited for
specific viral antigens.
摘要
这一提议的中心假设是,递送膜锚定的mRNA疫苗的效力
通过将免疫原定位于细胞外小泡(EVS,小膜-EV),可以改进免疫原。
真核细胞脱落的有限结构)。我们的理由是电动汽车为免疫原提供了一个天然的支架。
多聚体,同时也使膜结合的抗原能够访问抗原提呈细胞,既局部到
注射部位和引流淋巴结内。
为了将免疫原定位于电动汽车,并促进电动汽车的脱落,我们提出了两种免费的方法。在AIM
1,我们将把病毒的“晚期结构域”附加到免疫原的羧基末端。病毒的晚期区域很小
蛋白结构域,通常与基质或衣壳蛋白有关,被包膜病毒用来促进
萌芽和出土。我们发现,这些域可以断章取义;将较晚的域从
猫免疫缺陷病毒与SARS-CoV-2刺突蛋白免疫原结合可使该免疫原重获
定位于EVS,并将其免疫原性提高近两倍。我们将通过晚些时候的测试来扩展这项工作
与其他病毒不同的域名,因为它们有能力促进EV的本地化和/或生产。我们会彻底
确定这些EV的特征,以确定疫苗免疫原性的相关性。
在目标2中,我们将修改我们的免疫原以克服宿主抗病毒限制因子BST-2的活性
(也就是系留)。Tetherin通过将被包裹的病毒“拴”在宿主细胞上来抑制病毒的外泄
也通过同样的机制抑制EVS的释放。因此,我们将探索
对抗Tetherin的策略,以促进我们携带免疫原的EVS的释放。封套的
病毒已经进化出不同的Tetherin逃避策略,我们将尝试将这些策略整合到我们的
免疫基因设计。事实上,我们已经确定了SARS-CoV-2尖峰蛋白的一部分,我们怀疑
对系留蛋白的对抗负责。将这个S蛋白结构域戏剧性地整合到我们的免疫原中
增加从EV组织培养上清液中回收的免疫原量。我们还将
根据其他病毒的Tetherin抗性机制,探索类似的策略。
最后,在目标3中,针对不同的病毒包膜蛋白,提出了有希望的免疫原设计策略
免疫原(SARS-CoV-2、A型流感病毒、HIV)将在小鼠身上进行比较。这些测试将使我们能够
建立我们的疫苗免疫原在组织培养中的行为之间的相关性(数量和
电动汽车的特性、细胞毒性等)以及疫苗在体内的表现,并确定我们的
修改普遍提高疫苗效力,或者如果特定的免疫原设计更适合于
特定的病毒抗原。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael R. Farzan其他文献
Michael R. Farzan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael R. Farzan', 18)}}的其他基金
eCD4-mediated control of SIV infection in the brain
eCD4 介导的脑部 SIV 感染控制
- 批准号:
10698442 - 财政年份:2023
- 资助金额:
$ 18.96万 - 项目类别:
Safe, CRISPR/Cas-free B cell editing for therapeutic applications
用于治疗应用的安全、无 CRISPR/Cas 的 B 细胞编辑
- 批准号:
10725412 - 财政年份:2023
- 资助金额:
$ 18.96万 - 项目类别:
Improving mRNA vaccines with extracellular vesicle-associated immunogens
使用细胞外囊泡相关免疫原改进 mRNA 疫苗
- 批准号:
10573644 - 财政年份:2022
- 资助金额:
$ 18.96万 - 项目类别:
Engineering CAR-B cells for an HIV-1 functional cure
改造 CAR-B 细胞以实现 HIV-1 功能性治愈
- 批准号:
10514882 - 财政年份:2022
- 资助金额:
$ 18.96万 - 项目类别:
Engineering CAR-B cells for an HIV-1 functional cure
改造 CAR-B 细胞以实现 HIV-1 功能性治愈
- 批准号:
10844837 - 财政年份:2022
- 资助金额:
$ 18.96万 - 项目类别:
Therapeutic Use of an Enhanced Form of CD4-Ig
增强形式的 CD4-Ig 的治疗用途
- 批准号:
9970576 - 财政年份:2020
- 资助金额:
$ 18.96万 - 项目类别:
Therapeutic use of an enhanced form of CD4-Ig
增强型 CD4-Ig 的治疗用途
- 批准号:
10851165 - 财政年份:2020
- 资助金额:
$ 18.96万 - 项目类别:
Eliciting tyrosine-sulfated neutralizing antibodies recognizing the Env apex
引发识别 Env 顶点的酪氨酸硫酸化中和抗体
- 批准号:
10013483 - 财政年份:2020
- 资助金额:
$ 18.96万 - 项目类别:
相似海外基金
Construction of a conceptual model representing interpersonal situation in a mental nursing scene:From response to acting out of patients with borderline personality disorder
精神护理场景中人际情境概念模型的构建:从边缘型人格障碍患者的反应到行动
- 批准号:
26861973 - 财政年份:2014
- 资助金额:
$ 18.96万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Acting Out: Influence of an Acting Intervention on Cognition and Brain Function
行动:行动干预对认知和大脑功能的影响
- 批准号:
8643188 - 财政年份:2011
- 资助金额:
$ 18.96万 - 项目类别:
Acting Out: Influence of an Acting Intervention on Cognition and Brain Function
行动:行动干预对认知和大脑功能的影响
- 批准号:
8423324 - 财政年份:2011
- 资助金额:
$ 18.96万 - 项目类别:
Acting Out: Influence of an Acting Intervention on Cognition and Brain Function
行动:行动干预对认知和大脑功能的影响
- 批准号:
8231340 - 财政年份:2011
- 资助金额:
$ 18.96万 - 项目类别:
Acting Out: Influence of an Acting Intervention on Cognition and Brain Function
行动:行动干预对认知和大脑功能的影响
- 批准号:
8038225 - 财政年份:2011
- 资助金额:
$ 18.96万 - 项目类别:
Therapeutic understanding of "acting out" on the psychotherapeutic process of juvenile delinquents.
青少年犯罪心理治疗过程中“付诸行动”的治疗理解
- 批准号:
17530501 - 财政年份:2005
- 资助金额:
$ 18.96万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Acting-outによる英語表現指導の研究
Acting-out英语表达教学研究
- 批准号:
X00220----590728 - 财政年份:1980
- 资助金额:
$ 18.96万 - 项目类别:
Grant-in-Aid for Encouragement of Young Scientists (B)